🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Drug discovery platform Peptris raises Rs 70 Cr in Series A round

EntrackrEntrackr · 3h ago
Drug discovery platform Peptris raises Rs 70 Cr in Series A round
Medial

Drug discovery company Peptris has raised Rs 70 crore ($7.7 million) in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest along with participation from Tenacity Ventures, BYT Ventures, and other investors. The fresh capital will be used to advance its existing programs toward clinical readiness and to expand its pipeline over the next 24 months, and enhance teams across biology, chemistry, data science, and AI, Peptris said in a press release. Co-founded in 2019 by Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni, and Amit Mahajan, Peptris has created AI models to generate novel molecules and predict varied parameters that are critical to reduce failures in drug development. The approach has led to the discovery of Novel Chemical Entities (NCE), drug repurposing and rescue opportunities. According to the Bengaluru-based company, it addresses persistent problems in healthcare despite scientific advances, drug discovery remains slow, expensive, and failure-prone, leaving large unmet medical needs. This challenge is most acute in the pre-clinical stage, where time, capital, and scientific uncertainty often derail promising programs much before drugs reach the clinical stage. Peptris says that its platform not only generates novel molecules but also helps predict critical drug development parameters early. This enables faster and better-informed decision-making and has already resulted in the discovery of Novel Chemical Entities (NCEs) as well as drug repurposing and rescue opportunities, with multiple programs now advancing towards clinical development. The company plans to initiate several new NCE programs, alongside multiple drug repurposing and rescue programs (shelved clinical stage drugs of other companies). It follows a B2B engagement model, working closely with pharma, biotech, and select FMCG partners to license assets and co-develop programs. The startup focuses on therapeutic areas including rare diseases, inflammation, oncology, and women’s health to deliver a durable impact for patients, caregivers, and healthcare systems globally.

Related News

Agraga raises Rs 100 Cr in pre-Series B led by Bajaj Finserv Group

EntrackrEntrackr · 3m ago
Agraga raises Rs 100 Cr in pre-Series B led by Bajaj Finserv Group
Medial

Agraga raises Rs 100 Cr in pre-Series B led by Bajaj Finserv Group Digital freight forwarder Agraga has raised Rs 100 crore (around $12 million) in its pre-Series B round led by Bajaj Finserv Group, with participation from existing investor IvyCap Ventures and select global angel backers. Agraga had earlier raised Rs 70 crore in its Series A round in May 2023, led by IvyCap Ventures with participation from Alteria. The proceeds will be used to expand its cross-border logistics platform, strengthen its LCL (Less-than-Container Load) vertical, scale automation and visibility tools, and deepen its presence across major export hubs. Founded in 2021, Agraga provides a unified platform that integrates freight booking, customs, warehousing, and embedded financial services. The firm aims to simplify cross-border logistics for MSMEs and mid-market enterprises by offering real-time pricing, tracking, and compliance workflows. Agraga claims to have built its stack around four layers which includes discovery, tracking, execution, and data-driven decision-making. Agraga serves more than 700 customers and 1,000 vendors across 40 global trade lanes. It also partners with financial institutions including ICICI Bank and IDFC First Bank. Its subsidiary Byteport Logistics focuses on channel-partner aggregation for MSME and LCL customers. Bajaj Finserv backs Indian startups through its corporate venture arm, Bajaj Finserv Ventures, and its newer alternative investment subsidiary, with a focus on fintech, healthcare and technology.

Modulus Housing raises Rs 70 Cr in Series A round

EntrackrEntrackr · 2m ago
Modulus Housing raises Rs 70 Cr in Series A round
Medial

url: https://entrackr.com/news/modulus-housing-raises-rs-70-cr-in-series-a-round-10830476 Content: Modulus Housing raises Rs 70 Cr in Series A round Proptech startup Modulus Housing has raised Rs 70 crore ($7.83 million) in its Series A round led by Kalaari Capital, Hero, and Samarthya. The round also saw participation from SVAS, Sigma, Zetwerk founder Srinath, Sanjiv Rangrass, and other investors. This is the company’s first institutional funding. Founded in 2018 by Shreeram Ravichandran and P. Gobinath, Modulus Housing operates a factory-made construction model for modular buildings. It uses a cloud manufacturing network made up of partner factories and a proprietary product suite to produce structures for low-rise infrastructure. The company claims to run a profitable business with cumulative revenue of more than Rs 200 crore. The company’s operating revenue increased 38% to Rs 54 crore in FY24 from Rs 39 crore in the previous fiscal year. It didn’t disclose its FY25 numbers. The proceeds will be used for market expansion across India and select global markets, advanced R&D, a next-generation concrete modular system, and scaling its cloud manufacturing network. Modulus also plans to expand its green concrete technology for distributed infrastructure use cases. According to the company, it has completed more than 1,500 buildings across 21 Indian states and parts of Africa. These include modular hospitals, cold storage units, site offices, schools, and distributed infrastructure projects. Modulus Housing is headquartered in Chennai and plans to expand operations across India and emerging markets.

CENTA raises Rs 20 Cr in Series A1 round led by Colossa Ventures

EntrackrEntrackr · 10m ago
CENTA raises Rs 20 Cr in Series A1 round led by Colossa Ventures
Medial

CENTA raises Rs 20 Cr in Series A1 round led by Colossa Ventures Centre for Teacher Accreditation (CENTA) has raised Rs 20 crore ($2.33 million) in its Series A1 round led by Colossa Ventures, with participation from existing investor Discovery Assets and angel investors. The proceeds will be used to grow in India and other markets and to improve its technology systems. Started by Ramya Venkataraman and Priyanka Arya, CENTA provides teacher certification, upskilling, and teacher-as-a-service (TAAS), connecting teachers with full-time and part-time jobs. The platform claims to have 1.7 million teachers from over 100 countries and 100,000 schools. While India is its largest market, CENTA also has users in the UAE, Nigeria, the Philippines, Bangladesh, and Ghana. It is forming ties in the UK and US. CENTA runs the International Teaching Professional’s Olympiad and has received awards from Dun & Bradstreet, NITI Aayog, UNESCO, and others.

Ice cream brand Hocco raises Rs 115 Cr at Rs 2,000 Cr valuation

EntrackrEntrackr · 4m ago
Ice cream brand Hocco raises Rs 115 Cr at Rs 2,000 Cr valuation
Medial

Ice cream brand Hocco raises Rs 115 Cr at Rs 2,000 Cr valuation Premium ice cream brand Hocco has raised Rs 115 crore (around $13 million) in a fresh funding round led by existing backer Sauce.vc, taking the company’s valuation to Rs 2,000 crore. The funding comes less than three months after the firm raised $10 million in its Series B round led by Chona Family Office and Sauce.vc. It had also raised $12 million in its Series A round from the same investors at a valuation of Rs 600 crore ($70 million) in June last year. The fresh proceeds will be used towards expanding manufacturing capacity, strengthening cold-chain and logistics, scaling new product innovation, and extending its footprint across India and select global markets. By summer 2026, Hocco plans to reach 3 lakh litres in daily production capacity, making it one of the largest and most advanced ice cream manufacturing setups in the country. Founded by the Chona family, Hocco offers products across retail stores, quick commerce platforms, and out-of-home touchpoints. Its product line includes various flavours, formats, and packs designed for everyday use and modern retail channels. Hocco has built traction among consumers across retail, quick commerce, and travel-linked outlets through its ingredients, flavours, and distribution models. Hocco recently said it closed FY25 with revenue of Rs 220 crore. However, it did not comment on its loss numbers. According to startup data intelligence platform TheKredible, the company reported revenue of Rs 32.38 crore in FY24 with a Rs 20.23 crore loss. Besides legacy players such as Amul, Vadilal, and Hindustan Unilever (HUL), Hocco competes with new-age ice cream brands such as Walko Foods’ NIC, Hangyo, Go Zero, NOTO Ice Cream, among others.

Wint Wealth raises Rs 250 Cr in Series B round

EntrackrEntrackr · 1m ago
Wint Wealth raises Rs 250 Cr in Series B round
Medial

Wint Wealth raises Rs 250 Cr in Series B round Debt investment platform Wint Wealth has raised Rs 250 crore (nearly $28 million) in a Series B funding round led by Vertex Ventures Southeast Asia & India. The round also saw participation from existing investors including Eight Roads Ventures, 3one4 Capital, Arkham Ventures, and Rainmatter. Last month, Entrackr had exclusively reported on the company’s Series B round and valuation. Prior to this round, Wint Wealth had raised about $22 million (Rs 173 crore) from investors including Eight Roads Ventures, Zerodha, 3one4 Capital, and Unitary Fund. The company last raised a $17 million Series A round. The proceeds will be used to scale the platform, expand product offerings, and strengthen its credit and compliance infrastructure. Wint Wealth is also expected to deepen partnerships with issuers and improve distribution of fixed-income products to retail investors. Founded in 2020, Wint Wealth allows retail investors to invest in fixed-income products such as corporate bonds, securitized debt instruments, and non-convertible debentures (NCDs) asset classes that were largely limited to institutional investors earlier. The firm operates as a SEBI-registered Online Bond Platform Provider, enabling individuals to access listed bonds digitally. The Bengaluru-based startup has been focusing on building a transparent and regulated marketplace for debt investments, as more retail investors look beyond equities and mutual funds for stable returns. Wint Wealth is yet to file its FY25 numbers. In FY24, the company posted Rs 17.2 crore operating revenue with a loss of Rs 18 crore. According to data compiled by Entrackr, Indian wealthtech startups raised over $634 million across 51 deals involving 39 startups during 2024 and 2025. However, the sector saw limited large-ticket rounds, with only six deals of $30 million or more.

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 7m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.